Kang Zheng
Research Subjects
Kang Zheng has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Chuan Wang
Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hengyang, China
3 shared publications Weiwei Li
Department of Clinical Laboratory, The Second People's Hospital of Foshan, Foshan, China
3 shared publications- Yimou Wu
Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hengyang, China
3 shared publications - Guang-Gui Zeng
School of Medicine, Shanghai Jiao Tong University, 200127 Shanghai, China
2 shared publications Hongyu Yang
Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang Medical College, Institution of Pathogenic Biology, University of South China, Hengyang, China
2 shared publicationsLinglan Xu
Hunan Province Clinical Medical Research Center for Occupational Diseases, Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China, University of South China, Changsha, China
2 shared publications
Latest Publications
- 9 August 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 208, 107975
Treponema pallidum cytolytic toxin, Tp0649, induces apoptosis in THP-1 macrophages via the ERK MAPK, p38 MAPK, PI3K/AKT, and NF-κB signaling pathways
- 9 August 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 208, 107975
Treponema pallidum cytolytic toxin, Tp0649, induces apoptosis in THP-1 macrophages via the ERK MAPK, p38 MAPK, PI3K/AKT, and NF-κB signaling pathways
- Open Access
- 2 July 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (13)
The Regulatory Mechanisms of Treponema pallidum Enolase on Macrophages: From Enzymatic Activity to Signal Transduction
Syphilis, caused by the gram‐negative bacterium Treponema pallidum , remains a significant global public health threat. Despite the efficacy of antibiotic treatment in controlling syphilis, the pathogenic mechanisms of T. pallidum , particularly its interactions with the host immune system, are not well understood. This study aimed to investigate the potential immunomodulatory role of T. pallidum enolase (Eno) in promoting macrophage apoptosis through the P2X7R and reactive oxygen species (ROS)/NF‐κB pathways, offering new insights into the pathogen's immune evasion strategies. Bioinformatics analysis identified T. pallidum Eno as a hydrophilic cytoplasmic protein that plays a crucial role in glycolysis. In vitro experiments demonstrated that T. pallidum Eno can be successfully expressed and purified in Escherichia coli , resulting in significant induction of macrophage apoptosis. Mechanistic studies revealed that T. pallidum Eno activates caspase family members, decreases mitochondrial membrane potential, and triggers the apoptotic program in macrophages. Additionally, we found that T. pallidum Eno stimulates the production of ROS, subsequently activating the NF‐κB signaling pathway and promoting the transcription of apoptosis‐related genes. This study further highlights the role of T. pallidum Eno in modulating host immune responses by inducing the secretion of interleukin‐8, interleukin‐6, and interleukin‐1β, which are involved in macrophage chemotaxis and activation. Collectively, these findings suggest that T. pallidum may exploit the host inflammatory response to enhance its dissemination and evade immune clearance. The multifaceted functions of T. pallidum Eno in cell metabolism and immune regulation provide new insights into the pathogenesis of syphilis and offer potential targets for therapeutic intervention.
- 2 July 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (13)
Open AccessThe Regulatory Mechanisms of Treponema pallidum Enolase on Macrophages: From Enzymatic Activity to Signal Transduction
Syphilis, caused by the gram‐negative bacterium Treponema pallidum , remains a significant global public health threat. Despite the efficacy of antibiotic treatment in controlling syphilis, the pathogenic mechanisms of T. pallidum , particularly its interactions with the host immune system, are not well understood. This study aimed to investigate the potential immunomodulatory role of T. pallidum enolase (Eno) in promoting macrophage apoptosis through the P2X7R and reactive oxygen species (ROS)/NF‐κB pathways, offering new insights into the pathogen's immune evasion strategies. Bioinformatics analysis identified T. pallidum Eno as a hydrophilic cytoplasmic protein that plays a crucial role in glycolysis. In vitro experiments demonstrated that T. pallidum Eno can be successfully expressed and purified in Escherichia coli , resulting in significant induction of macrophage apoptosis. Mechanistic studies revealed that T. pallidum Eno activates caspase family members, decreases mitochondrial membrane potential, and triggers the apoptotic program in macrophages. Additionally, we found that T. pallidum Eno stimulates the production of ROS, subsequently activating the NF‐κB signaling pathway and promoting the transcription of apoptosis‐related genes. This study further highlights the role of T. pallidum Eno in modulating host immune responses by inducing the secretion of interleukin‐8, interleukin‐6, and interleukin‐1β, which are involved in macrophage chemotaxis and activation. Collectively, these findings suggest that T. pallidum may exploit the host inflammatory response to enhance its dissemination and evade immune clearance. The multifaceted functions of T. pallidum Eno in cell metabolism and immune regulation provide new insights into the pathogenesis of syphilis and offer potential targets for therapeutic intervention.
- 19 June 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (1) , 1159-1185
Development of a novel multi-epitope vaccine against Ureaplasma urealyticum infection through reverse vaccinology approach
Ureaplasma urealyticum (U. urealyticum) is a sexually transmitted pathogen often causing urogenital tract disorders. The growing challenge of multidrug-resistant strains poses a significant risk for the treatment of U. urealyticum infections. To date, no licensed vaccines are available, and previous attempts to create secure and efficient prophylaxis have been failed. Recent studies have adopted an immunoinformatic strategy based on reverse vaccinology to detect antigenic proteins which are appropriate for the creation of a multi-epitope vaccine. The multi-epitope subunit vaccine, incorporating eleven T-cell and seven B-cell epitopes along with the adjuvant, exhibited strong antigenicity and did not induce allergic responses. Moreover, molecular docking as well as dynamic simulations were utilized to investigate the interaction within the vaccine-adjuvant complex. The prospective effectiveness of the vaccine was verified via immune simulation experiments. Therefore, the vaccine developed in this study represents an effective multi-epitope solution for immunization against U. urealyticum, waiting for further experimental analysis.
- 19 June 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (1) , 1159-1185
Development of a novel multi-epitope vaccine against Ureaplasma urealyticum infection through reverse vaccinology approach
Ureaplasma urealyticum (U. urealyticum) is a sexually transmitted pathogen often causing urogenital tract disorders. The growing challenge of multidrug-resistant strains poses a significant risk for the treatment of U. urealyticum infections. To date, no licensed vaccines are available, and previous attempts to create secure and efficient prophylaxis have been failed. Recent studies have adopted an immunoinformatic strategy based on reverse vaccinology to detect antigenic proteins which are appropriate for the creation of a multi-epitope vaccine. The multi-epitope subunit vaccine, incorporating eleven T-cell and seven B-cell epitopes along with the adjuvant, exhibited strong antigenicity and did not induce allergic responses. Moreover, molecular docking as well as dynamic simulations were utilized to investigate the interaction within the vaccine-adjuvant complex. The prospective effectiveness of the vaccine was verified via immune simulation experiments. Therefore, the vaccine developed in this study represents an effective multi-epitope solution for immunization against U. urealyticum, waiting for further experimental analysis.
- Open Access
- 19 March 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1551437
A comprehensive strategy for the development of a multi-epitope vaccine targeting Treponema pallidum, utilizing heat shock proteins, encompassing the entire process from vaccine design to in vitro evaluation of immunogenicity
Background: Treponema pallidum, the causative spirochete of syphilis, is primarily transmitted through sexual contact and has emerged as a significant global health concern. To address this issue, enhancing diagnostic capabilities, strengthening public health interventions, and developing a safe and effective vaccine are critical strategies.Objective: This study employed an immunoinformatics approach to design a vaccine with high immunogenic potential, targeting the heat shock proteins of T. pallidum.Methods: Based on heat shock proteins of T. pallidum, we predicted B-cell, CTL, and HTL epitopes and all the selected epitopes were linked to construct a multi-epitope vaccine. Antigenicity, toxicity, and allergenicity of epitopes were checked by VaxiJen 2.0, AllerTOP v2.0, and ToxinPred servers. After constructing the multi-epitope vaccine, we subsequently predicted its secondary and tertiary protein structures. After refining and validating the modeled structure, we utilized advanced computational approaches, including molecular docking and dynamic simulations, to evaluate the binding affinity, compatibility, and stability of the vaccine-adjuvant complexes. Eventually, in silico cloning was conducted to optimize protein expression and production.Results: The multi-epitope subunit vaccine we developed was constructed by seven cytotoxic T lymphocyte epitopes, five helper T lymphocyte epitopes, four B cell epitopes, and adjuvant β-defensin. An adjuvant was used to enhance immune responses, all of which were linked to one another using GPGPG, AAY, and KK linkers, respectively. The population coverage of the designed vaccine was 94.41% worldwide. Molecular docking and MD simulations indicated strong binding interactions with TLR1/2, TLR-2 and TLR-4 in a stable vaccine-receptor complex. The final designed vaccine, composed of 502 amino acids, theoretically exhibits high antigenicity and immunity, capable of inducing both humoral and cellular immune responses.Conclusion: The vaccine developed in this study theoretically represents a safe and potent multi-epitope prophylactic strategy against T. pallidum, subject to further experimental validation to ascertain its actual protective efficacy.
- 19 March 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1551437
Open AccessA comprehensive strategy for the development of a multi-epitope vaccine targeting Treponema pallidum, utilizing heat shock proteins, encompassing the entire process from vaccine design to in vitro evaluation of immunogenicity
Background: Treponema pallidum, the causative spirochete of syphilis, is primarily transmitted through sexual contact and has emerged as a significant global health concern. To address this issue, enhancing diagnostic capabilities, strengthening public health interventions, and developing a safe and effective vaccine are critical strategies.Objective: This study employed an immunoinformatics approach to design a vaccine with high immunogenic potential, targeting the heat shock proteins of T. pallidum.Methods: Based on heat shock proteins of T. pallidum, we predicted B-cell, CTL, and HTL epitopes and all the selected epitopes were linked to construct a multi-epitope vaccine. Antigenicity, toxicity, and allergenicity of epitopes were checked by VaxiJen 2.0, AllerTOP v2.0, and ToxinPred servers. After constructing the multi-epitope vaccine, we subsequently predicted its secondary and tertiary protein structures. After refining and validating the modeled structure, we utilized advanced computational approaches, including molecular docking and dynamic simulations, to evaluate the binding affinity, compatibility, and stability of the vaccine-adjuvant complexes. Eventually, in silico cloning was conducted to optimize protein expression and production.Results: The multi-epitope subunit vaccine we developed was constructed by seven cytotoxic T lymphocyte epitopes, five helper T lymphocyte epitopes, four B cell epitopes, and adjuvant β-defensin. An adjuvant was used to enhance immune responses, all of which were linked to one another using GPGPG, AAY, and KK linkers, respectively. The population coverage of the designed vaccine was 94.41% worldwide. Molecular docking and MD simulations indicated strong binding interactions with TLR1/2, TLR-2 and TLR-4 in a stable vaccine-receptor complex. The final designed vaccine, composed of 502 amino acids, theoretically exhibits high antigenicity and immunity, capable of inducing both humoral and cellular immune responses.Conclusion: The vaccine developed in this study theoretically represents a safe and potent multi-epitope prophylactic strategy against T. pallidum, subject to further experimental validation to ascertain its actual protective efficacy.
- 22 October 2023
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (1) , 102161
A new perspective on the current and future development potential of ABCG1
- 22 October 2023
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (1) , 102161
A new perspective on the current and future development potential of ABCG1
- 16 October 2023
- Published by Elsevier in Microbial Pathogenesis
- Vol. 185, 106392
Research progress on the mechanism of Treponema pallidum breaking through placental barrier
- 16 October 2023
- Published by Elsevier in Microbial Pathogenesis
- Vol. 185, 106392
Research progress on the mechanism of Treponema pallidum breaking through placental barrier
- 5 October 2023
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (1) , 102116
The Potential Relationship Between Cardiovascular Diseases and Monkeypox
- 5 October 2023
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (1) , 102116
The Potential Relationship Between Cardiovascular Diseases and Monkeypox
- 4 October 2023
- Published by Elsevier in Microbial Pathogenesis
- Vol. 184, 106374
Immunisation with the glycolytic enzyme enolase inhibits dissemination of Treponema pallidum in C57BL/6 mice
- 4 October 2023
- Published by Elsevier in Microbial Pathogenesis
- Vol. 184, 106374
Immunisation with the glycolytic enzyme enolase inhibits dissemination of Treponema pallidum in C57BL/6 mice
- Open Access
- 10 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (8) , 7013
Protective Immunity against Chlamydia psittaci Lung Infection Induced by a DNA Plasmid Vaccine Carrying CPSIT_p7 Gene Inhibits Dissemination in BALB/c Mice
Chlamydia psittaci (C. psittaci), a zoonotic pathogen, poses a potential threat to public health security and the development of animal husbandry. Vaccine-based preventative measures for infectious diseases have a promising landscape. DNA vaccines, with many advantages, have become one of the dominant candidate strategies in preventing and controlling the chlamydial infection. Our previous study showed that CPSIT_p7 protein is an effective candidate for a vaccine against C. psittaci. Thus, this study evaluated the protective immunity of pcDNA3.1(+)/CPSIT_p7 against C. psittaci infection in BALB/c mice. We found that pcDNA3.1(+)/CPSIT_p7 can induce strong humoral and cellular immune responses. The IFN-γ and IL-6 levels in the infected lungs of mice immunized with pcDNA3.1(+)/CPSIT_p7 reduced substantially. In addition, the pcDNA3.1(+)/CPSIT_p7 vaccine diminished pulmonary pathological lesions and reduced the C. psittaci load in the lungs of infected mice. It is worth noting that pcDNA3.1(+)/CPSIT_p7 suppressed C. psittaci dissemination in BALB/c mice. In a word, these results demonstrate that the pcDNA3.1(+)/CPSIT_p7 DNA vaccine has good immunogenicity and immunity protection effectiveness against C. psittaci infection in BALB/c mice, especially pulmonary infection, and provides essential practical experience and insights for the development of a DNA vaccine against chlamydial infection.
- 10 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (8) , 7013
Open AccessProtective Immunity against Chlamydia psittaci Lung Infection Induced by a DNA Plasmid Vaccine Carrying CPSIT_p7 Gene Inhibits Dissemination in BALB/c Mice
Chlamydia psittaci (C. psittaci), a zoonotic pathogen, poses a potential threat to public health security and the development of animal husbandry. Vaccine-based preventative measures for infectious diseases have a promising landscape. DNA vaccines, with many advantages, have become one of the dominant candidate strategies in preventing and controlling the chlamydial infection. Our previous study showed that CPSIT_p7 protein is an effective candidate for a vaccine against C. psittaci. Thus, this study evaluated the protective immunity of pcDNA3.1(+)/CPSIT_p7 against C. psittaci infection in BALB/c mice. We found that pcDNA3.1(+)/CPSIT_p7 can induce strong humoral and cellular immune responses. The IFN-γ and IL-6 levels in the infected lungs of mice immunized with pcDNA3.1(+)/CPSIT_p7 reduced substantially. In addition, the pcDNA3.1(+)/CPSIT_p7 vaccine diminished pulmonary pathological lesions and reduced the C. psittaci load in the lungs of infected mice. It is worth noting that pcDNA3.1(+)/CPSIT_p7 suppressed C. psittaci dissemination in BALB/c mice. In a word, these results demonstrate that the pcDNA3.1(+)/CPSIT_p7 DNA vaccine has good immunogenicity and immunity protection effectiveness against C. psittaci infection in BALB/c mice, especially pulmonary infection, and provides essential practical experience and insights for the development of a DNA vaccine against chlamydial infection.
- Open Access
- 23 November 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 987662
Alternative strategies for Chlamydia treatment: Promising non-antibiotic approaches
Chlamydia is an obligate intracellular bacterium where most species are pathogenic and infectious, causing various infectious diseases and complications in humans and animals. Antibiotics are often recommended for the clinical treatment of chlamydial infections. However, extensive research has shown that antibiotics may not be sufficient to eliminate or inhibit infection entirely and have some potential risks, including antibiotic resistance. The impact of chlamydial infection and antibiotic misuse should not be underestimated in public health. This study explores the possibility of new therapeutic techniques, including a review of recent studies on preventing and suppressing chlamydial infection by non-antibiotic compounds.
- 23 November 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 987662
Open AccessAlternative strategies for Chlamydia treatment: Promising non-antibiotic approaches
Chlamydia is an obligate intracellular bacterium where most species are pathogenic and infectious, causing various infectious diseases and complications in humans and animals. Antibiotics are often recommended for the clinical treatment of chlamydial infections. However, extensive research has shown that antibiotics may not be sufficient to eliminate or inhibit infection entirely and have some potential risks, including antibiotic resistance. The impact of chlamydial infection and antibiotic misuse should not be underestimated in public health. This study explores the possibility of new therapeutic techniques, including a review of recent studies on preventing and suppressing chlamydial infection by non-antibiotic compounds.